As denosumab is a frequently used drug in patients with advanced malignant diseases, and rebound hypercalcemia with low PTH levels may raise the suspicion for skeletal metastases, awareness of this rebound effect may be of particular relevance for further patient management in such settings. This evidence concerns the gene PTH and hypercalcemia disease.